Articles published by BeiGene
![](https://mms.businesswire.com/media/20220526005609/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220511006144/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220504005602/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220428006315/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220427006162/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220427005648/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting
April 27, 2022
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220427005497/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220421005433/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220419005450/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220415005045/en/1199527/5/BGNE_Logo_0821.jpg)
China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell Carcinoma
April 15, 2022
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://mms.businesswire.com/media/20220408005100/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220406005427/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220314005833/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220222005575/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220222005574/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220217005344/en/1363223/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220131005943/en/1344890/4/Dr.-Dugan-HS.jpg)
![](https://mms.businesswire.com/media/20220128005107/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220124005223/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220120005178/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20220106005053/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20211212005018/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211211005001/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211210005022/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021
December 10, 2021
From BeiGene
Via Business Wire
Tickers
BGNE
![](https://www.businesswire.com/images/bwlogo_extreme.png)
![](https://mms.businesswire.com/media/20211202005063/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211123006162/en/1199527/5/BGNE_Logo_0821.jpg)
![](https://mms.businesswire.com/media/20211122005809/en/1199527/5/BGNE_Logo_0821.jpg)
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational TYK2 Inhibitor BGB-23339
November 22, 2021
From BeiGene
Via Business Wire
Tickers
BGNE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.